ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1671461
Desensitization of TRPA1 by Dimethyl Itaconate attenuates Acute and Chronic Pain in mice
Provisionally accepted
Sen Xu1
Jia-Yue Zhao2
Jun-Yi Ma2
Xia-Lin Cui2
Jia-Hui Lin2
Shiyu Sun2
Si-Jia Liu2
Guokun Zhou2
Jiang-Tao Zhang2
Peipei Kang3
Tong Liu2*- 1Other
- 2Nantong University, Nantong, China
- 3Nantong Tumor Hospital, Nantong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chronic pain remains a significant clinical challenge due to the limited efficacy of current analgesics. Dimethyl itaconate (DMI), a cell-permeable derivative of itaconate with known anti-inflammatory and immunomodulatory properties, has recently shown promise in alleviating pain. However, the mechanisms by which DMI modulates acute and chronic pain remain unclear. In the present study, we found that DMI directly activates and desensitizes the transient receptor potential ankyrin 1 (TRPA1) channel, a critical calcium-permeable ion channel implicated in various pain states. Molecular docking analysis and functional assays using calcium imaging revealed possible covalent interactions between DMI and key TRPA1 residue (cysteine 621). To further explore the possible therapeutic effects of DMI for chronic pain, we investigated the possible analgesic effects of DMI in multiple chronic pain mouse models. Single intraplantar injection of DMI induced transient mechanical hypersensitivity in a dose-dependent manner, while repeated injection of DMI failed to induce pain responses in mice. Furthermore, repeated intraperitoneal administration of DMI alleviated pain-related behaviors in a variety of acute pain models, including allyl isothiocyanate (AITC)- and formalin-induced acute inflammatory pain. Moreover, DMI alleviated pain-related behaviors in chronic pain models, including dextran sulfate sodium (DSS)-induced colitis, complete Freund's adjuvant (CFA)-induced inflammatory pain, oxaliplatin-induced neuropathic pain, and bone cancer pain in mice. Finally, the anti-hyperalgesia effects of DMI on CFA-induced inflammatory pain was abolished in TRPA1 knockout mice. Together, our findings demonstrate that DMI acts as a novel TRPA1 agonist for attenuating acute and chronic pain, possible through TRPA1 desensitization. Thus, DMI may be further developed as a potential therapeutic strategy for the treatment of acute and chronic pain.
Keywords: Dimethyl itaconate, TRPA1, Desensitization, Pain, Dorsal root ganglion
Received: 23 Jul 2025; Accepted: 19 Sep 2025.
Copyright: © 2025 Xu, Zhao, Ma, Cui, Lin, Sun, Liu, Zhou, Zhang, Kang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tong Liu, tongliu@ntu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.